Coriell Life Sciences

About

Coriell Life Sciences (CLS) is a precision medicine and pharmacogenomics company founded in 2013. It focuses on advancing personalized healthcare through genetic testing. CLS combines pharmacogenomics with precision medicine to create tailored diagnosis and treatment plans. The company was acquired by InformedDNA, enhancing its capabilities in genomic insights. CLS offers a range of services and products aimed at medication safety and personalized medicine. Its Corigen® program provides population-scale medication risk management for health plans, employers, and health systems. The company also delivers expert pharmacogenomic research analysis and comprehensive medication management systems. Additionally, CLS has expertise in infectious disease management and healthcare analytics, helping to identify effective therapies based on genomic profiles. The company serves a variety of healthcare organizations, including large employers, health plans, health systems, and research institutions. CLS maintains extensive genetic and non-genetic knowledge repositories to support its clinical and research efforts, contributing to improved health outcomes through its comprehensive management programs.